Bank of New York Mellon Corp Buys 4,404 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of New York Mellon Corp lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,832 shares of the specialty pharmaceutical company's stock after purchasing an additional 4,404 shares during the quarter. Bank of New York Mellon Corp owned about 0.59% of ANI Pharmaceuticals worth $6,845,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. State Street Corp raised its stake in ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after buying an additional 58,698 shares during the period. Pacer Advisors Inc. raised its position in shares of ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after purchasing an additional 565,910 shares during the period. JPMorgan Chase & Co. raised its position in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock valued at $25,373,000 after purchasing an additional 17,314 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $191,776 in the last 90 days. 12.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of recent research reports. StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, March 14th. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $79.75.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded up $0.29 on Wednesday, reaching $64.51. 278,412 shares of the company's stock were exchanged, compared to its average volume of 238,469. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -117.35 and a beta of 0.63. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a fifty day simple moving average of $58.79 and a 200-day simple moving average of $58.07. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.